Goetz is the creator of “Drug Story,” a new podcast about the disease business. Biologically, how the GLP-1 is delivered into the body should make little difference: It’s the same peptide, just in a different formulation. But in our human reality, it ...

For more than a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that "Bromo- and Extra-Terminal domain" (BET) proteins help activate,